For early-stage breast cancer cases with ER+ and PR+ status, histology was not associated with a difference in BCSS. Alternatively, ILC cases that were ER− or PR− had an increased BCSS compared with receptor-matched IDC cases. These findings add to the growing evidence supporting ILC as a more favorable histology, which is important for guiding treatment and prognostication.
Justin M. Mann, Weisi Yan, Guojiao Wu, Dattatreyudu Nori, Akkamma Ravi; New York Presbyterian-Weill Cornell Medical Center
BACKGROUND: Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two most common breast cancer histologies. IDC is more common and confers a worse prognosis than ILC. Biomarkers, including estrogen receptor (ER) and progesterone receptor (PR) status, improve prognostic accuracy and will likely be added to a future edition of the American Joint Committee on Cancer (AJCC) TNM classification. As a whole, patients with an ER- and PR-negative phenotype have a worse prognosis when compared with receptor-positive phenotypes. Using Surveillance, Epidemiology, and End Results (SEER) data, we performed statistical analysis to determine if receptor-matched statuses in IDC compared with ILC differ in overall outcome.
METHODS: A total of 50,658 cases of early-stage (I–IIB) breast cancer (groups = IDC and ILC) diagnosed from 1998–2002 who underwent breast conservation surgery were queried from the SEER 18 database. Patients without known ER or PR receptor status were excluded. Kaplan-Meier survival analysis and log-rank test were used to compare breast cancer cause-specific survival (BCSS).
RESULTS: There were 2,852 (5.63%) cases of ILC and 47,806 (94.37%) cases of IDC in this analysis. A total of 40,099 (79.2%) cases were ER+, and 34,901 (68.9%) cases were PR+. For ER+ cases, 60-month BCSS was 98% for ILC and 97.7% for IDC (P = .79). For ER− cases, 60-month BCSS was 95.5% for ILC and 89.7% for IDC (hazard ratio [HR] = 0.45; P = .02). For PR+ cases, 60-month BCSS was 98.3% for ILC and 97.8% for IDC (P = .35). For PR− cases, 60-month BCSS was 96.1% for ILC and 92.0% for IDC (HR = 0.77; P = .03).
CONCLUSION: For early-stage breast cancer cases with ER+ and PR+ status, histology was not associated with a difference in BCSS. Alternatively, ILC cases that were ER− or PR− had an increased BCSS compared with receptor-matched IDC cases. These findings add to the growing evidence supporting ILC as a more favorable histology, which is important for guiding treatment and prognostication.
Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.